OMN-6 is under clinical development by Omnix Medical and currently in Phase I for Ventilator Associated Pneumonia (VAP). According to GlobalData, Phase I drugs for Ventilator Associated Pneumonia (VAP) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OMN-6’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OMN-6 overview

OMN-6 is under development for the treatment of multi-drug resistant Acinetobacter baumannii infections, hospital associated bacterial pneumoniae (HABP/VABP), blood-stream infections (BSI) and complicated urinary-tract infections (cUTI). It is administered through intravenous route. It acts by targeting bacterial membrane. The drug candidate is being developed based company’s technology which utilizes biochemical engineering to enable the synthesis of soluble, stable, safe and highly-potent antimicrobial-peptides.

Omnix Medical overview

Omnix Medical is a biopharmaceutical company developing an arsenal of novel antibiotic agents for the treatment of infections involving drug-resistant bacteria. Omnix Medical is headquartered in Jerusalem, Israel.

For a complete picture of OMN-6’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.